"All three types of myasthenia gravis, based on antibody status, can have similar symptoms," said Henry Kaminski, MD, of George Washington University in Washington, D.C. "Most patients have droopy ...

Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory ...

Background Myasthenia gravis (MG) represents a heterogeneous group of autoantibody-mediated diseases targeting the neuromuscular junction. Extraocular muscles (EOMs) are highly susceptible to ...

Background: Cytokines play a crucial role in instigating inflammation and generating pathogenic autoantibodies at the neuromuscular junction in individuals suffering from myasthenia gravis (MG). The ...

This article provides a thorough overview of the pathophysiology and current treatment options for myasthenia gravis, an autoimmune and antibody-mediated neuromuscular disease.

Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis ...

A retrospective analysis of patients with acetylcholine receptor antibody (AChR-Ab)-positive generalized myasthenia gravis (MG) who underwent thymectomy found that a majority of them had good long ...

The main goal of the project is to create a unified technological platform for medical rehabilitation by monitoring the implementation of exercises set remotely.In the proposed case, the user ...